Desloratadine
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Desloratadine: H1 antihistamine → nasal cavity disease
One-Sentence Summary
Desloratadine is an oral antihistamine (H1 receptor blocker) used for allergy-related conditions. The TxGNN model predicts it may be relevant to nasal cavity disease, but there are no registered clinical trials and only 2 preclinical publications, so the evidence is weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | nasal cavity disease |
| TxGNN Prediction Score | 0.9987 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, desloratadine belongs to the H1 antihistamine class. It blocks histamine at H1 receptors, which drives sneezing, itching, and nasal discharge in allergic nasal conditions.
“Nasal cavity disease” is a broad, non-specific term. The model’s signal most likely reflects overlap with allergic and vasomotor rhinitis, uses that are already established for this drug class, rather than a distinct new use. A narrower, clearly defined nasal condition would be needed to judge whether this is truly a repurposing opportunity.
The supporting literature is limited to animal models. One is a rat model of allergic rhinitis that tested hesperidin and thymol, not desloratadine. The other is a feline nasal congestion model that studied loratadine, a related drug, plus montelukast, with desloratadine looked at only in a side experiment with pseudoephedrine. Neither study directly examines desloratadine for nasal cavity disease in a clinical setting, so they count as indirect evidence only. Because no cited study directly addresses the predicted disease, the evidence level is L5.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30488351 | 2019 | Preclinical animal study (rat) | Eur Arch Otorhinolaryngol | Hesperidin and thymol in ovalbumin-induced allergic rhinitis in rats; not specific to desloratadine |
| 19769798 | 2009 | Preclinical animal study (cat) | Am J Rhinol Allergy | Loratadine plus montelukast reduced nasal congestion in a feline model; desloratadine was studied with pseudoephedrine in a side experiment |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 61135 | Desolid M 5mg/10mg Tablet | Strip of 10 tablets | Not recorded |
| 63132 | Desolate 10mg Tablet | Strip of 10 tablets | Not recorded |
| 59208 | Dest 5mg Tablet | Strip of 10 tablets | Not recorded |
| 62951 | Drewex 5mg Tablet | Strip of 10 tablets | Not recorded |
| 60919 | Desgic 5 Tablet | Strip of 10 tablets | Not recorded |
At least 20 single-ingredient licences are currently valid, and the list may be partial.
Safety Considerations
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for safety information.
- Drug Interactions: 266 potential interactions are recorded, but severity levels are unclassified. Examples include cimetidine, omeprazole, pantoprazole, lansoprazole, metformin, morphine, simvastatin, epinephrine, prednisone and hydrocortisone. These need individual review before any new-use plan.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication is too broad to act on and likely overlaps with existing allergic and vasomotor rhinitis use. There are no clinical trials, and the only literature is indirect animal-model work.
To proceed, the following is needed:
- A specific, well-defined nasal condition that is clearly distinct from the existing use
- Clinical studies that directly test desloratadine in that condition
- Mechanism of action data
- Package insert warnings and contraindications from the local product labels
- Review of the drug interactions and a safety plan
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.